Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes

Inclusion Criteria

• •Type 1 diabetes mellitus since more than one year, treated by insulin since at least one year
• •Treatment by insulin pump since at least 6 months
• •Glycated hemoglobin (HbA1c) below 10.5% at inclusion visit
• •For women of child bearing age, no current pregnancy and use of an efficient contraception during the whole research participation
• •Agreement on no use of drugs or products used for reduction of blood glucose levels, such as metformin or GLP1 analogs, except if this therapy has been used for at least 3 months before study start
• •Agreement on stopping closed-loop insulin delivery after acetaminophen use and 4 following hours
• •Agreement on suspending use of patient CGM device during the study period while study CGM will be used
• •Access to the internet and a mobile phone network at home
• •Agreement on following study procedures
• •Affiliation to the French social security system or a similar healthcare coverage system
• •Mandatory written informed consent